Ananda Scientific Inc., a clinical-stage drug development company, and Benta SAS have signed a Memorandum of Understanding (MOU).

PTSD is a chronic and debilitating condition that affects millions of people worldwide. Despite its significant prevalence and devastating impact on patients, families, and communities, there has been ...

Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understandin ...

Eli Lilly and Novo are preparing to announce new drug pricing deals with the White House, including for their blockbuster ...

PhaseV, a leader in AI/ML for clinical development, today announced it has received three significant 2025 industry honors, highlighting the growing market traction and adoption of its platform for ...

The global Clinical Analytics Market, valued at US$27.65 billion in 2024, stood at US$33.09 billion in 2025 and is projected to advance ...

The Health Canada authorization marks an important regulatory milestone in the NS002 development program. This clearance confirms the acceptability of the proposed trial design, supporting safety data ...

Ultimately, achieving Universal Health Care will depend on our collective ability to invest more where it matters, procure ...

PE: What makes TrumpRx different from other government-run health programs? O’Dell: TrumpRx is different in that its following on coattails in things that are already proven in other parts of the ...

The Ohio State University College of Veterinary Medicine has appointed Leah Dorman, DVM, a 1995 graduate of the college, as ...

HaloMD today announced its partnership with Dr. Lorna Breen Heroes' Foundation, adding its support to the foundation's ALL IN for Mental Health program. The new partnership will help the Foundation ...

Designed by clinicians for clinicians, BOS improves clinical outcomes, financial performance, and value-based care results. LOS ANGELES, CA / ACCESS Newswire / November 11, 2025 / Precise Behavioral, ...